Would a sufficient initial vancomycin therapy affect the Prognosis of MRS infection- a multicenter clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003563

Enrollment

Unknown

Registered

2013-08-17

Start date

2013-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MRS infection

Interventions

Trial Group:Administrating following the Guidline

Control:administrating follow description

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged >18years; 2. MRS infection which need vancomycin therapy; 3. Patients would be MRS infection so that vancomycin should be administrated.

Exclusion criteria

Exclusion criteria: 1. Vancomycin allergy; 2. Pregnancy; 3. Psychiatric disorders or final stage; 4. Patients refuse; 5. Cannot take the patients serum sample.

Design outcomes

Primary

Measure	Time frame
Serum Drug concentration;Turnover;Bacteria;	—

Secondary

Measure	Time frame
Drug adverse effection ;	—

Countries

China

Contacts

Public ContactWu Dawei

Qilu Hospital of Shandong University

wdw.55@163.com+86 13791122767

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026